Downregulation and Prognostic Performance of MicroRNA 224 Expression in Prostate Cancer | Zendy

Konstantinos Mavridis | Zendy; Konstantinos Stravodimos | Zendy; Andreas Scorilas | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Downregulation and Prognostic Performance of MicroRNA 224 Expression in Prostate Cancer

Author(s) -

Konstantinos Mavridis,

Konstantinos Stravodimos,

Andreas Scorilas

Publication year - 2012

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2012.191502

Subject(s) - prostate cancer , oncology , pca3 , biomarker , medicine , microrna , overdiagnosis , prostate , cancer , proportional hazards model , biology , gene , biochemistry

The extensive use of prostate-specific antigen as a general prostate cancer biomarker has introduced the hazards of overdiagnosis and overtreatment. Recent studies have revealed the immense biomarker capacity of microRNAs (miRNAs) in prostate cancer. The aim of this study was to analyze the expression pattern of miR-224, a cancer-related miRNA, in prostate tumors and investigate its clinical utility.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research